New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:43 EDTARGSArgos Therapeutics shares should be bought ahead of data, says JMP Securities
JMP Securities reports that Dr. Figlin, a thought leader in kidney cancer and lead investigator for Argos's pivotal ADAPT study, expects Argos' kidney cancer treatment, AGS-003, to be granted approval timelines that will give it a first-mover advantage. Dr. Figlin believes that AGS-003 and checkpoint inhibitors could move hard-to-tolerate TKI therapies to second line. The firm recommends buying Argos ahead of data for its HIV therapy, AGS-004, which the firm thinks will create a positive read-through for AGS-003.
News For ARGS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
10:02 EDTARGSArgos Therapeutics breaks ground on new 100K square foot facility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use